# Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

> **NCT06079359** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Hypophosphatasia

## Interventions

- **DRUG:** ALXN1850
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06079359
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-14
- **Primary completion:** 2026-01-06
- **Final completion:** 2028-08-24
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06079359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06079359, "Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06079359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*